Sientra (NASDAQ:SIEN) Upgraded to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Sientra (NASDAQ:SIEN) from a sell rating to a hold rating in a research note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “

A number of other analysts have also weighed in on SIEN. SVB Leerink dropped their price objective on Sientra from $6.50 to $5.30 and set an outperform rating for the company in a research note on Tuesday, May 12th. Craig Hallum dropped their price objective on Sientra from $14.00 to $9.00 and set a buy rating for the company in a research note on Thursday, March 12th. Stephens dropped their price objective on Sientra from $10.00 to $5.00 and set an overweight rating for the company in a research note on Monday, March 23rd. Canaccord Genuity dropped their price objective on Sientra from $9.00 to $5.00 and set a buy rating for the company in a research note on Friday, May 15th. Finally, Maxim Group increased their price objective on Sientra from $5.00 to $8.00 in a research note on Thursday, June 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. Sientra has a consensus rating of Buy and an average price target of $6.13.

Shares of SIEN opened at $3.87 on Friday. The firm has a market cap of $192.63 million, a P/E ratio of -1.48 and a beta of 1.45. The stock has a 50 day simple moving average of $3.79 and a two-hundred day simple moving average of $4.65. The company has a debt-to-equity ratio of 1.02, a current ratio of 2.24 and a quick ratio of 1.72. Sientra has a 1 year low of $1.00 and a 1 year high of $9.71.

Sientra (NASDAQ:SIEN) last issued its earnings results on Monday, May 11th. The medical instruments supplier reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.08). The firm had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $18.70 million. Sientra had a negative return on equity of 101.94% and a negative net margin of 134.87%. On average, equities analysts anticipate that Sientra will post -1.64 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the stock. Citigroup Inc. raised its holdings in shares of Sientra by 6,407.7% during the fourth quarter. Citigroup Inc. now owns 62,995 shares of the medical instruments supplier’s stock valued at $563,000 after acquiring an additional 62,027 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Sientra by 55.7% during the fourth quarter. Bank of New York Mellon Corp now owns 243,492 shares of the medical instruments supplier’s stock valued at $2,176,000 after acquiring an additional 87,129 shares in the last quarter. EAM Investors LLC bought a new position in shares of Sientra during the fourth quarter valued at approximately $2,657,000. State Street Corp raised its holdings in shares of Sientra by 32.1% during the fourth quarter. State Street Corp now owns 727,107 shares of the medical instruments supplier’s stock valued at $6,500,000 after acquiring an additional 176,835 shares in the last quarter. Finally, Schroder Investment Management Group raised its holdings in Sientra by 1.7% in the first quarter. Schroder Investment Management Group now owns 1,902,776 shares of the medical instruments supplier’s stock worth $3,863,000 after purchasing an additional 31,763 shares in the last quarter. Institutional investors own 76.99% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names.

Read More: Analyst Ratings

Get a free copy of the Zacks research report on Sientra (SIEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.